iCAD Inc. (ICAD)
1.96
0.05 (2.62%)
At close: Jan 14, 2025, 3:59 PM
2.00
2.04%
After-hours Jan 14, 2025, 06:00 PM EST
undefined% (undefined)
| Bid | 1.84 |
| Market Cap | 52.02M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.2 |
| PE Ratio (ttm) | -9.8 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 2 |
| Volume | 66,990 |
| Avg. Volume (20D) | 278,501 |
| Open | 1.98 |
| Previous Close | 1.91 |
| Day's Range | 1.93 - 2.04 |
| 52-Week Range | 1.18 - 2.65 |
| Beta | undefined |
About ICAD
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm tha...
Industry Medical - Devices
Sector Healthcare
IPO Date Dec 13, 1984
Employees 67
Stock Exchange NASDAQ
Ticker Symbol ICAD
Website https://www.icadmed.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ICAD stock is "Strong Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
iCAD Inc. is scheduled to release its earnings on Mar 11, 2025,
during market hours.
Analysts project revenue of $4.50M, reflecting a -5.08% YoY shrinking and earnings per share of -0.06, making a 200.00% increase YoY.
Analysts project revenue of $4.50M, reflecting a -5.08% YoY shrinking and earnings per share of -0.06, making a 200.00% increase YoY.
1 month ago ·
Source
+9.49%
iCAD shares are trading higher after the company a...
Unlock content with
Pro Subscription
2 months ago ·
Source
-23.5%
Icad shares are trading lower after the company reported worse-than-expected Q3 revenue results.
